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Simple Summary: Lynch syndrome (LS) and constitutional mismatch repair deficiency (CMMRD)
are hereditary disorders which significantly increase a person’s risk of developing a variety of cancers
such as colorectal, endometrial, brain and, for CMMRD also, haematological malignancies. This
increased cancer risk is due to inherited mutations in specific types of DNA repair genes, which
hampers repair of mispaired or damaged bases during DNA replication. As a consequence, somatic
mutations rapidly accumulate and typically include insertions and deletions (indels) in microsatellites
that potentially can give rise to neoantigens. These neoantigens open up avenues for neoantigen-
targeting immune therapies. Here, we aim to discuss the major obstacles that are encountered in
developing such a therapy, including the heterogenous tumour profile of LS and CMMRD patients
which challenge the selection of suitable neoantigens and potential resistance to immune checkpoint
inhibitor therapy. In addition, we give a perspective on how to overcome the encountered obstacles.
Abstract: Lynch syndrome (LS) and constitutional mismatch repair deficiency (CMMRD) are hereditary
disorders characterised by a highly increased risk of cancer development. This is due to germline
aberrations in the mismatch repair (MMR) genes, which results in a high mutational load in tumours
of these patients, including insertions and deletions in genes bearing microsatellites. This generates
microsatellite instability and cause reading frameshifts in coding regions that could lead to the generation
of neoantigens and opens up avenues for neoantigen targeting immune therapies prophylactically and
therapeutically. However, major obstacles need to be overcome, such as the heterogeneity in tumour
formation within and between LS and CMMRD patients, which results in considerable variability in the
genes targeted by mutations, hence challenging the choice of suitable neoantigens. The machine-learning
methods such as NetMHC and MHCflurry that predict neoantigen- human leukocyte antigen (HLA)
binding affinity provide little information on other aspects of neoantigen presentation. Immune escape
mechanisms that allow MMR-deficient cells to evade surveillance combined with the resistance to immune
checkpoint therapy make the neoantigen targeting regimen challenging. Studies to delineate shared
neoantigen profiles across patient cohorts, precise HLA binding algorithms, additional therapies to counter
immune evasion and evaluation of biomarkers that predict the response of these patients to immune
checkpoint therapy are warranted.
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1. Introduction
Lynch Syndrome (LS) is an autosomal dominantly inherited disorder resulting from
monoallelic germline aberrations in genes that are involved in DNA mismatch repair
(MMR) machinery [1]. The four MMR genes that are implicated in the disorder are MLH1,
MSH2, MSH6 and PMS2 [2]. Patients with LS inherit a pathogenic germline variant in only
one allele while the remaining wild type allele is somatically inactivated by point mutations,
loss of heterozygosity or epigenetic silencing due to promoter hypermethylation [3,4]. In
1999, two reports described the phenotype within LS families including children who
carried homozygous germline mutations in the MLH1 gene. The children in both families
displayed haematological malignancies in early childhood and clinical features that were
previously known from neurofibromatosis type 1 [5,6]. Since then, individuals who inherit
bi-allelic germline mutations in one of the MMR genes have been identified to suffer from
constitutional mismatch repair deficiency (CMMRD). This rare syndrome is inherited
recessively with homozygous or compound heterozygous germline mutations in the DNA
MMR genes, most commonly PMS2 and MSH6 [7].
LS increases a person’s risk of colorectal cancer (CRC) by 40–80% and endometrial
cancer by 15–60% [8]. Individuals with LS are also more prone to a variety of cancers
among which are urothelial (0.4–20%), ovarian cancers (4–12%), gastric cancers (<10%),
brain tumours and also cancers of the biliary tract [9–12]. Similarly, CMMRD patients have
an increased risk of developing CRC in adolescence or young adulthood. In patients with
CMMRD 50% develop malignant brain tumours while 40% develop cancers of the digestive
tract [13]. The risk of developing haematological malignancies is as high as 30% [13]. In
fact, the penetrance of cancers in CMMRD is one of the highest among childhood cancer
syndromes, and it is extremely uncommon for a patient not to have developed cancer
by the third decade [14]. The increased cancer risk in LS patients stems from the loss of
the second functional MMR allele which results in accumulation of somatic mutations
leading to carcinogenesis [15]. In contrast, tumorigenesis in CMMRD patients does not
depend on second hit mutations since the biallelic loss of MMR functioning itself renders
the cells unable to repair damaged DNA and hence lose genomic integrity [16]. Figure 1
summarises the key features of LS and CMMRD.
The accumulation of somatic mutations and genomic instability, especially in mutation
prone regions, e.g., regions of repetitive nucleotide sequences, results in non-synonymous
mutations. These mutations give rise to proteins with altered amino acid sequences called
frameshift peptides (FSPs) that can give rise to neoantigens [17,18]. Neoantigens make
an attractive target for immunotherapies since they have not been subjected to central
and thymic tolerance and are solely expressed by tumour cells [19]. Tumours with high
mutational burden such as those in LS and CMMRD patients are more likely to give rise
to neoantigens and hence provide more opportunities for targeted therapies [18]. Despite
the presence of technological facilities that help with the efficient identification of such
neoantigens, therapies henceforth developed are still in nascent stages when compared
to neoantigen targeting therapies in melanoma which have shown tumour regression in
patients [20]. This demands further probe into the aspects that are impairing a successful
neoantigen targeting regimen in LS and CMMRD. This review aims to assess the challenges
that neoantigen targeting in LS and CMMRD is currently facing with a perspective on
overcoming them.




Figure 1. Schematic view on the differences between LS and CMMRD with a focus on colorectal cancer. Abbreviations 
used- LS: Lynch Syndrome, CMMRD: Constitutional mismatch repair deficiency syndrome, MMR: mismatch repair, CRC: 
colorectal cancer, MSS: microsatellite stable, MSI: microsatellite instable. 
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2. Mismatch Repair Deficiency and Microsatellite Instability
DNA damage can occur endogenously through metabolic processes inside a cell and
through exogenous processes like environmental agents. The repair pathways involved
in the repair of damaged DNA are broadly classified as base excision repair, homologous
recombination, non-homologous end joining, nucleotide excision repair and MMR [21,22].
The role of the DNA MMR system is to maintain genomic integrity through base pair
and small insertion-deletion (indel) corrections that are erroneously generated during
DNA replication [23]. The most important components of the DNA MMR system are
the MutS and MutL complexes. In its functional state, MutSα, consisting of MSH2 and
MSH6 proteins, recognises single base indels. Functional MutSβ, consisting of MSH2
and MSH3 proteins, recognises indels consisting of 2–8 nucleotides. MutLα, consisting of
MLH1 and PMS2, or MutLβ, consisting of MLH1 and PMS1, binds together with the MutS
complex as a heterodimer along with replicative factors to initiate repair of the mismatched
nucleotides. Since MSH2 and MLH1 are the proteins shared by both components of their
respective MutS and MutL complexes, a mutation in the respective genes will completely
retard all MMR activity whereas a mutation in PMS2 or MSH6 genes will reduce MMR
activity towards single nucleotide indels only [24]. Tumours arise from clonal expansion of
cells that have inactivation of both alleles of a MMR gene that can either be somatic or of
germline origin.
Indels commonly occur in regions of repetitive nucleotide sequences called microsatel-
lites, where the template and the primer strands are prone to slippage (i.e., dissociation
and re-annealing) during replication. Such mismatches are not repaired in MMR deficient
cells, resulting in an incorrect number of repeat units between the template and newly syn-
thesised strand. The microsatellite alterations can lead to a shift in the translational reading
frame and therefore generation of FSPs [25]. This genetic alteration is termed microsatellite
instability (MSI) and is a characteristic of LS-associated cancers. The process is briefly sum-
marised in Figure 2. MSI is not specific for LS and CMMRD, approximately 15% of sporadic
colorectal cancers also demonstrate MSI that most often originates by hypermethylation of
the MLH1 promotor and somatic bi-allelic inactivation of MMR genes [26–28]. While all
microsatellites have an equal chance for mutations, differences in their mutation frequency
can occur due the length of the repeat and the nature of the relevant nucleotide sequence.




Figure 2. Schematic view of the DNA mismatch repair pathway. Abbreviations used- MMR: mismatch repair. 
3. Clinical Management of LS and CMMRD 
Since LS patients are at risk of early onset CRC, regular colonoscopy surveillance 
starting from age 20–25, is essential to diagnose early lesions with the intent to prevent 
development of CRC. For LS patients, regular coloscopy is quite a burden and does not 
prevent the formation of new lesions, pointing to the need for other preventive measures 
[29]. There is evidence of reduced CRC risk in LS patients and sporadic MMR gene muta-
tion carriers who took 600 mg/day aspirin for at least 2 years [30]. However, there are 
concerns regarding the risk of bleeding events in young patients [31]. Since a subset of 
chemotherapeutics rely on a functional MMR system to induce tumour damage, the effi-
cacy of such drugs in MMR-deficient tumours such as in LS or CMMRD has been poor 
[32]. In fact worse prognosis was seen for stage II MSI high (MSI-H) colon cancer patients 
in a randomised trial administering adjuvant based 5-Flurouracil chemotherapy (5-FU) as 
compared to microsatellite stable (MSS) tumours, as a result of a lesser effectiveness of 5-
FU in these MSI-H cancers [33]. The resistance of MMR deficient cells to drugs such as 
temozolomide, an alkylating agent used to treat glioblastoma multiforme (GBM), can lead 
to a greater risk of developing second primary tumours in CMMRD patients because of 
the accumulation of unrepaired mutations [7]. MMR-deficient cells are also more resistant 
to cisplatin treatment in comparison to MMR-proficient cells [34,35]. 
MSI-H cancers have a higher density of infiltrating lymphocytes compared to MSS 
cancers, which has been demonstrated to correlate with a better prognosis [36,37]. This 
observation highlights the potential of immunotherapy. In fact, LS-associated cancers 
have more pronounced local immune responses as compared to sporadic MSI-H cancers 
[38]. However, increased infiltration is counteracted by increased checkpoint protein ex-
pression which is an important mechanism by which the tumour microenvironment in-
hibits immune responses. By chronically expressing checkpoint receptors such as CTLA-
4, PD-1, TIM-3, LAG-3 and more, T-cells become functionally exhausted and dysfunc-
tional [39]. The upside of this checkpoint protein overexpression phenotype is the strong 
efficacy of immune checkpoint inhibitor therapies that have shown positive outcomes in 
MMR-deficient tumours across a range of malignancies [40]. This outcome has already led 
to FDA approval of the PD-1 antibody pembrolizumab for the treatment of refractory 
dMMR/MSI-H solid malignancies, and the PD-1 antibody nivolumab with or without the 
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3. Clinical Management of LS and CMMRD
Since LS patients are at risk of early onset CRC, regular colonoscopy surveillance
starting from age 20–25, is essential to diagnose early lesions with the intent to prevent
development of CRC. For LS patients, regular coloscopy is quite a burden and does not
prevent the formation of new lesions, pointing to the need for other preventive mea-
sures [29]. There is evidence of reduced CRC risk in LS patients and sporadic MMR gene
mutation carriers who took 600 mg/day aspirin for at least 2 years [30]. However, there
are concerns regarding the risk of bleeding events in young patients [31]. Since a subset of
chemotherapeutics rely on a functional MMR system to induce tumour damage, the efficacy
of such drugs in MMR-deficient tumours such as in LS or CMMRD has been poor [32].
In fact worse prognosis was seen for stage II MSI high (MSI-H) colon cancer patients in
a randomised trial administering adjuvant based 5-Flurouracil chemotherapy (5-FU) as
compared to microsatellite stable (MSS) tumours, as a result of a lesser effectiveness of
5-FU in these MSI-H cancers [33]. The resistance of MMR deficient cells to drugs such as
temozolomide, an alkylating agent used to treat glioblastoma multiforme (GBM), can lead
to a greater risk of developing second primary tumours in CMMRD patients because of the
accumulation of unrepaired mutations [7]. MMR-deficient cells are also more resistant to
cisplatin treatment in comparison to MMR-proficient cells [34,35].
MSI-H cancers have a higher density of infiltrating lymphocytes compared to MSS
cancers, which has been demonstrated to correlate with a better prognosis [36,37]. This
observation highlights the potential of immunotherapy. In fact, LS-associated cancers have
more pronounced local immune responses as compared to sporadic MSI-H cancers [38].
However, increased infiltration is counteracted by increased checkpoint protein expression
which is an important mechanism by which the tumour microenvironment inhibits im-
mune responses. By chronically expressing checkpoint receptors such as CTLA-4, PD-1,
TIM-3, LAG-3 and more, T-cells become functionally exhausted and dysfunctional [39].
The upside of this checkpoint protein overexpression phenotype is the strong efficacy of im-
mune checkpoint inhibitor therapies that have shown positive outcomes in MMR-deficient
tumours across a range of malignancies [40]. This outcome has already led to FDA approval
of the PD-1 antibody pembrolizumab for the treatment of refractory dMMR/MSI-H solid
malignancies, and the PD-1 antibody nivolumab with or without the CTLA-4 antibody
ipilimumab for the treatment of dMMR/MSI-H CRC after 5-FU treatment [41]. In a trial
combining nivolumab and ipilimumab (NCT02060188), a disease control rate of 79% for
>12 weeks was reported irrespective of clinical LS history [42]. Phase II studies have shown
the safety and durable efficacy of nivolumab in patients with advanced MMR-deficient
CRC (NCT01876511) where an immune-related progression free survival rate was seen
for 78% of patients with MMR-deficient cancers as compared to the 11% of patients that
had MMR-proficient cancers. However, it is important to note that while objective re-
sponses were seen in 100% of all non-LS-associated MMR-deficient cancers, only 27% (3 of
11 patients) of LS-associated cancers showed an objective response [40]. In a case study
of a patient with LS-associated metastatic CRC, pembolizumab treatment reduced the
metabolic activity of the cancerous lesions and improved symptoms [43]. Additionally,
another case report from a LS patient with pancreatic adenocarcinoma and metastatic
liver disease showed excellent clinical response with regards to liver lesion shrinkage after
only one cycle of pembrolizumab treatment [44]. Nivolumab has also been reported to
have significant efficacy at inducing an anti-tumour response and prolonging survival
for two patients with CMMRD recurrent glioblastoma [45]. In another young child with
CMMRD-associated GBM, nivolumab therapy showed a 60% reduction in tumour size
and improved symptoms [46]. These groundbreaking results have amplified interest in
the potential use of checkpoint inhibitors in combination with other therapeutics in the
treatment of MMR-deficient cancers in LS and CMMRD.
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4. Targeting Neoantigens in LS and CMMRD
Tumours that arise due to LS or CMMRD are highly mutated compared to their MMR-
proficient countertypes. For instance, paediatric glioblastomas in CMMRD patients exhibit
an ultra-high number of nonsynonymous mutations (≥250 mut/Mb) which contrasts
the low frequency of nonsynonymous mutations (<1 mut/Mb) seen in the majority of
glioblastomas [47,48].
The high tumour mutational burden (TMB) generated because of the MMR defect
can result in neoantigen formation. These neoantigens are formed when indels result
in a frameshift of the amino acid sequence in the C-terminal of the protein producing
an FSP, that acts as a substrate for antigen processing and presentation via the major
histocompatibility complex (MHC) class I and II molecules [49]. Once presented on the cell
surface, they are referred to as neoantigens and could act as targets for tumour-infiltrating
CD4+ helper T lymphocytes and CD8+ cytotoxic T lymphocytes (CTLs). Various clinical
trials employing neoantigen based therapies for CRC are already ongoing [50].
Several studies have identified neoantigens in LS patients that are highly immuno-
genic, for example TGFβRII, CASP5, TAF1B, HT001 and OGT [51,52]. More importantly,
CTLs specific to these neoantigens have also been detected in LS patients. CTLs directed
against TGFβRII and CASP5 neoantigens are capable of lysing MSI-H colon carcinoma
cells as shown in in-vitro assays [52–54]. Some of these mutations are found to be shared
between LS and non-LS MSI-H CRCs hence calling attention to neoantigen-targeting thera-
pies encompassing more patient groups [55]. Moreover CTLs specific for a wide range of
neoantigens have been found to be induced already in patients that have not yet developed
a cancerous lesion i.e., in healthy LS carriers [52]. This points towards the strong immune
surveillance mechanisms in LS patients whereby the immune system recognises and pos-
sibly has the potential of eradicating MMR-deficient cells even before they develop into
cancer. These observations strongly argue in favour of a promising efficacy of neoantigen-
targeting therapy for therapeutic and preventive purposes in LS and CMMRD with added
significance for prophylactic purposes to prevent admission of chemotherapy.
Strong lymphocyte infiltration in MMR deficient cancers makes it a prime target for
checkpoint inhibitor therapy, some of which have been discussed above. In addition, it
opens avenues for other immunotherapies such as dendritic cell (DC) vaccination. DC
vaccination may lead to the specific enhancement of immune responses against neoantigens
and hence lesser toxicity as opposed to general immune activation in response to check-
point inhibition. This is already being investigated in a DC vaccination trial in LS mutation
carriers, to assess the feasibility of DC vaccination loaded with frameshift derived neoanti-
gens associated with MSI (NCT01885702). Preliminary data show that after DC vaccination,
neoantigen-specific T-cells are detectable in blood and delayed type hypersensitivity (DTH)
tests, without the induction of severe adverse events [56]. Similarly, in another Phase I/II
trial (NCT01461148) in LS patients, a vaccine against the neoantigens HT001, AIM2 and
TAF1B has been shown to be well tolerated with no severe adverse effects in any patient,
and induced humoral and cellular responses in all patients [57]. Another recent case study
investigated the use of a combination of autologous DCs producing IL-12, nivolumab
(anti-PD1 receptor) and radiotherapy for the treatment of a CMMRD patient that showed a
complete therapeutic response [58]. Another promising immunotherapeutic approach was
demonstrated preclinically, with the adoptive transfer of CTLs with an engineered TCR-
directed against a FSP of the TGFβRII gene. This particular TGFβRII frameshift mutation is
reported in 90% of MSI-H CRC [59]. The adoptive transfer induced significant reduction in
tumour load in a xenograft mouse model [60]. However, this approach has not been tested
in humans yet.
As promising as these strategies are, there are still many obstacles that need to
be overcome.
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5. Challenges of Neoantigen Targeting in LS and CMMRD
The development of a neoantigen vaccine basically begins with the identification of
suitable neoantigens through sequencing techniques and computational modelling. The
predicted neoantigens are then synthesised chemically and tested for recognition by CTLs.
The subsequent design and delivery of the vaccine is optimised and tested preclinically
depending on the type of cancer it is targeting and several other factors [18,61]. The process
is detailed in Figure 3. For a vaccine to mount the most potent anti-tumour response,
it must induce a significant increase in the quantity of neoantigen-specific T cells that
have a high affinity to this particular neoantigen. This is a complicated task and multiple
challenges are encountered.




Figure 3. Schematic view of the different steps of developing a neoantigen targeting therapy and the challenges encoun-
tered in each step. 1–2 Whole exome sequencing from resected tumours or adenomas identifies indels; 3–4 The predicted 
neoantigens are assessed for HLA binding affinity through machine-learning methods; 5–6 Predicted strong binders are 
tested for immunogenicity in-vitro through biochemical and immunological assays; 7 Immunogenic neoantigen can be 
formulated in different forms before being administered in the patient. Abbreviations—TCR: T cell receptor, LC-MS: Liq-
uid chromatography-Mass spectrometry. 
5.1. Tumour Heterogeneity 
Heterogeneity of tumours can be classified into (1) interpatient heterogeneity which 
refers to the differences in the clinical manifestation of the same type of tumour in differ-
ent patients (2) intertumoural heterogeneity which refers to the acquisition of a different 
set of mutations and other histological and clinical characteristics in metastatic lesions or 
second primary tumours compared to the primary tumour and (3) intratumoural hetero-
geneity which refers to the different phenotypes and genotypes of groups of cells that 
form the same tumour [62]. Since LS gives rise to tumours with complex carcinogenic 
pathways, all three heterogeneities have implications for neoantigen-targeting. 
Interpatient heterogeneity in LS/CMMRD patients is associated with the MMR gene 
mutation seen in the patient. Several studies have come to a consensus in defining signif-
icant differences in cancer risks associated with mutation of MMR genes. While mutations 
in MLH1 were mostly indicative of an increased risk of CRC, MSH2 and MSH6 mutations 
were seen to predispose to extracolonic malignancies such as endometrial and urothelial 
cancers in addition to CRC and PMS2 to a lower life time cancer risk and more atypical 
malignancies [63,64]. The heterogeneity in tumour manifestation is also seen in CMMRD 
cases where MLH1/MSH2 mutations predominantly give rise to, but are not limited to, 
highly aggressive haematological malignancies, while MSH6 and PMS2 mutations mostly 
give rise to brain tumours before the age of 10 years. Forty percent of the patients with 
homozygous PMS2 mutations give rise to second primary malignancies, while only 22% 
Figure 3. Schematic view of the different steps of developing a neoantigen targeting therapy and the challenges encountered
in each step. 1–2 Whole exome sequencing from resected tumours or adenomas identifies indels; 3–4 The predicted
neoantigens are assessed for HLA binding affinity through machine-learning methods; 5–6 Predicted strong binders are
tested for immunogenicity in-vitro through biochemical and immunological assays; 7 Immunogenic neoantigen can be
formulated in differ t forms before being administered in the patient. Abbrevi tion —TCR: T cell receptor, LC-MS: Liquid
chrom ography-Mass spectrometry.
5.1. Tumour Heterogeneity
Heterogeneity of tumours can be classified into (1) interpatient heterogeneity which
refers to the differences in the clinical manifestation of the same type of tumour in different
patients (2) intertumoural heterogeneity which refers to the cquisition of a different set of
mutatio s and other histological and clinical charact ristics in metastat c lesi ns or s co d
primary umours compa ed t the primary tumour and (3) intratumoural heterogeneity
which refers to he different heno ypes and genotypes of groups of cells that form the
same tumour [62]. Since LS gives rise to tumours with complex carcinogenic pathways, ll
three terog neities have impli ations for neoantigen-targeting.
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Interpatient heterogeneity in LS/CMMRD patients is associated with the MMR gene
mutation seen in the patient. Several studies have come to a consensus in defining signifi-
cant differences in cancer risks associated with mutation of MMR genes. While mutations
in MLH1 were mostly indicative of an increased risk of CRC, MSH2 and MSH6 mutations
were seen to predispose to extracolonic malignancies such as endometrial and urothelial
cancers in addition to CRC and PMS2 to a lower life time cancer risk and more atypical
malignancies [63,64]. The heterogeneity in tumour manifestation is also seen in CMMRD
cases where MLH1/MSH2 mutations predominantly give rise to, but are not limited to,
highly aggressive haematological malignancies, while MSH6 and PMS2 mutations mostly
give rise to brain tumours before the age of 10 years. Forty percent of the patients with
homozygous PMS2 mutations give rise to second primary malignancies, while only 22% of
patients with homozygous MLH1/MSH2 develop second primary malignancies. This is
because patients with homozygous MLH1/MSH2 develop more aggressive malignancies
and have much lower chance of surviving the first malignancy as compared to PMS2
mutation carrier patients [13]. The striking interindividual heterogeneity in LS-associated
CRC also results from differences in molecular pathways involved [36]. It was initially
described that MMR deficiency was a secondary event that enhanced tumorigenesis of pre-
formed polyps resulting from APC mutations [15]. On the contrary, recent evidence from
MMR-deficient crypt foci (MMR-DCF) has pointed to two more carcinogenic pathways
which describe MMR deficiency as the initiator and not the accelerator of carcinogenesis.
MMR-DCF can give rise to (1) cancers developing from intra-mucosal neoplastic lesions af-
ter accumulation of mutations in genes such as APC, KRAS or RNF43, and (2) immediately
invasive cancers arising from non-polypus lesions through mutations in CTNNB1 or TP53
genes [65]. It is also of significance to note that while hypermethylation pattern and MSI
tumours are enriched on the right side of the colon, not all tumours on the right side of
the colon are hypermutated [66]. Moreover, although MMR deficiency itself is a common
event for all carcinogenic pathways described in LS-CRC, patients have heterogenous
risks of developing hypermutated polyps which highly express neoantigens or polyps
with a low mutational burden and therefore a lower expression of neoantigens depending
on the mutation of the MMR gene and the carcinogenic pathway involved [50,67]. In an
interesting study among LS-CRC patients a contrast was seen that divided the patients in
two groups where a majority of tumours in the first group had MLH1 mutations and conse-
quently greater MS slippages leading to higher TMB. In contrast, the majority of tumours
in second group had MSH2 mutations, lesser DNA damage and lower TMB resembling an
MSS-sporadic CRC phenotype [68]. Hence predicting a neoantigen profile that is widely
shared among most patients is more difficult. A study comparing MSI patterns between
adult MMR deficient tumours and paediatric CMMRD patients, found that adult MMR
deficient tumours exhibited highly mutated microsatellite loci hotspots while paediatric
tumours from CMMRD patients did not. For instance, the mutation in microsatellite region
of gene ACVR2 is shared among 45% of adult MMR deficient tumours but only 11% of
paediatric tumours from CMMRD patients [69].
Intertumour heterogeneity was observed in an LS-CRC patient in whom the first
tumour was shown to be MSH2 positive but another more proximally located tumour was
completely MSH2 deficient [70]. For CRC cases in general, a discordance has been shown
between the mutations harboured in primary tumours and metastases. In a few CRC cases,
the primary tumour has been shown to have a MSS phenotype while the corresponding
liver metastasis were highly mutated with apparent MSI [71]. This certainly demands more
studies into the mutational profile of metastases in LS-CRC patients.
Presence of intratumoural heterogeneity in LS-CRC has been highlighted by the fact
that the resulting neoantigens have variable expression patterns such that not a single
neoantigen is known to be present on all MSI cells [52]. Despite this overwhelming
heterogeneity, neoantigens arising from mutations in OGT, TGFBR2, CASP5, BAX, ASTE1,
ACVR2, TAF1B, PTEN are considered to be common as they have been shown to be present
in >50% of MSI-H tumours [52,72]. A recent study concerning 10 LS and 5 CMMRD
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patients identified mutations in the coding regions of RNASET2 and TFDP1 genes shared
among and between majority of LS and CMMRD patients in their small cohort. This paves
the way for shared neoantigen identification and subsequent targeting [73].
Since heterogeneity works to the tumours’ advantage, an interesting suggestion in
this regard is to increase a tumours homogeneity by selecting for a tumour clone that
is resistant to initial treatment and further treating it with immunotherapy so that the
immune system has a more homogenous target [74]. This also provides scope for an initial
off-the-shelf immunotherapy targeting shared neoantigens. Moreover, it has been shown
that DC tumour infiltration is significantly greater in MSI-H CRCs compared to MSS CRCs,
this could play a role in epitope spreading by diversification of the immune response to
other antigens presented by the tumour [75]. Recently, the role of circulating tumour DNA
and circulating tumour cells as liquid biopsies is being explored as a non-invasive means
of predicting metastasis and response to therapy for CRC. For instance, circulating tumour
DNA can shed light on the heterogenous tumour landscape and molecular characterisation
of the circulating tumour cells can help in the identification of tumour clones resistant to
therapy [76]. This is a promising tool that must be investigated in LS and CMMRD patients
as well.
However, choosing a suitable neoantigen in CMMRD patients is particularly difficult
because, in contrast to LS patients in whom only (pre)malignant cells are completely MMR-
deficient, in CMMRD patients MMR deficiency is present in all cells and therefore the
neoantigens could be expressed in healthy cells of the patient as well. Vaccination must
therefore be done with caution so as to not induce a major auto-immune response.
5.2. Neoantigen Selection
As indicated in step 1 of Figure 3, neoantigen identification starts with sequencing the
tumour exome and optional RNA sequencing to identify the indels in microsatellite regions
which are then analysed through computational modelling to predict the neoantigens
that have the strongest binding affinity to the patients’ MHC molecules [77]. Among the
various prediction models, NetMHC is the most commonly used software to predict the
MHC:peptide binding affinity. This model relies on an extensive list of affinity measures
described by the Immune Epitope Database and Analysis Resource (IEDB) and on the
database for MHC ligands and peptide motifs (SYFPIETHI) [78]. The IEDB has curated
information from over 700,000 experiments to reflect the binding of an epitope specific
TCR or MHC molecule to an experimentally tested antigen and the SYFPEITHI contains a
dense collection of various MHC class I and II molecules and peptide motifs [79]. While
a sizeable number of sequencing studies has been conducted for LS related and sporadic
MSI-H cancers providing data for such simulations, data of CMMRD related cancers is
still sparse.
In spite of the availability of extensive data on MHC molecule structures, the pre-
diction models fail to account for the various other steps of epitope processing such as
the efficiency of the MHC ligand processing and the abundance of the precursor protein
giving rise to the neoantigen itself. Additionally, some transcripts can be sensitive to
non-sense mediated decay in which case they are not expressed by the mutant cells [80].
In addition, the protein cleavage and the efficiency of the transporter associated with
antigen presentation (TAP) play a major role in peptide-MHC binding, which is difficult to
predict. Moreover, the neoantigen prediction models shed little light on cross-reactivity
with self-peptides [81]. Some neoantigen cancer vaccine trials have shown that more
polyfunctional CD4+ T cells than CD8+ T cells are induced in melanoma and glioblastoma
patients despite the neoantigens being predicted to bind strongly to human leukocyte
antigen I (HLA-I) molecules [82]. This has been attributed to the promiscuous binding
properties of HLA-II proteins among other factors. While this points towards the ambiguity
of MHC binding prediction algorithms, this effect is not undesirable because CD4+ T cells
have been shown to aid in tumour clearance and similar effects must be investigated in
LS/CMMRD vaccination trials as well.
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Since most prediction models mentioned above rely on HLA-binding strength of
predicted neoantigens, the neoantigens with lower affinity to HLA complex but having
high immunogenicity are often overlooked [81]. It is important to realise that neoantigens
that have high recognisable potential might be unable to induce effective T cell responses
because of being insufficiently present in the tumour [83]. There is also evidence for the
presence of subdominant and cryptic neoantigens that are not capable of inducing an
immune response naturally but can be activated through vaccination [84]. This could be
an opportunity that is currently underutilised in searching for shared neoantigens in high
mutational burden tumours found in LS and CMMRD.
In a study involving members of two unrelated families with LS, a neoantigen pre-
diction algorithm called OncoPeptVAC was used to predict the immunogenicity of in
silico derived peptides resulting from a common germline mutation in the MLH1 gene,
observed in LS-associated cancer unaffected and affected members of both families [85].
This prediction algorithm also predicts the binding affinity of the neoantigen to the TCR
and was able to predict that neoantigens resulting from the germline MLH1 mutation,
would be non-immunogenic. It predicted that weaker binding of the neoantigen to the TCR
outweighs the strong HLA binding on the antigen presenting cell, thereby rendering it non-
immunogenic. This is preferable because neoantigens arising from germline mutations can
be present in all cells and vaccination against these can trigger an auto-immune response.
Moreover, using the same algorithm, neoantigens predicted from somatic mutations of
the genes MSH6, PIGO and AXIN2 observed in the LS-CRC tumour of one of the affected
family members, was shown to induce interferon gamma (IFNγ) releasing T cell responses.
Another neoantigen prediction pipeline to analyse the distribution of frameshift
mutations and their corresponding epitopes in MSI-H endometrial, colorectal, and stomach
cancers revealed five FSPs of SLC35F5, SEC31A, TTK, SETD1B and RNF43 genes that were
shared among these cancer types, however no respective immunogenicity was tested [86].
Albeit, with the same pipeline, a total of nine FSPs for MSI-H endometrial cancers were
discovered which had strong HLA-binding affinity and were also highly immunogenic.
This predictability of immunogenic neoantigens was achieved by including longer peptides
which encode multiple epitopes and by pooling the neoantigen-compatible HLA types
resulting in a diverse poly-allelic HLA ligandome. However the presence of a high or low
load of these shared polyepitope frameshift mutations was not found to be significantly
associated with survival benefit of the respective patients [86]. Recently, a novel neoantigen-
prediction tool called the REgression based FRAMEshift quantification algorithm (ReFrame)
was developed that utilises a linear series of mathematical equations to account for stutter
artifacts or the undesirable frameshift products that might result during slippage in the PCR
amplification step [87]. Identification of indels arising from MSI was made more specific by
this tool because it was coupled with a novel immunological scoring method. This method
identifies immunologically relevant neoantigens by analysing the strength of binding
to MHC and the prevalence of the corresponding MHC allele in a specific population.
Since many different neoantigen prediction algorithms are now being developed, it is also
important for the information to be shared among researchers to improve the features,
sensitivity and accuracy of these algorithms. The Synapse platform developed by Sage
Bionetworks is one such platform, which allows researchers to organise their data and
codes and collaborate with other researchers.
It is also suggested to include hydrophobic and aromatic amino acid residues and
differences in non-anchor residues to enhance immunogenicity [88]. Further biochemical
assays can be used to determine peptide-HLA stability.
5.3. Vaccine Formulation
There are several different methods of formulating and delivering the neoantigen
vaccine to a patient which include DNA-, RNA-, protein- or peptide-based delivery meth-
ods [86]. As mentioned above, for MMR deficient CRC patients, a phase I/II clinical trial
with a peptide vaccine directed against AIM2, HT001 and TAF1B neoantigens employing
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the adjuvant Montanide ISA-51VG showed no severe toxicity in any of the patients while
cellular and humoral immunogenic responses were seen in all 16 patients included in the
study [57]. However, the authors do not comment on the efficacy of the vaccine in terms
of tumour-specific cytotoxicity. This study suggests that protein/peptide-based vaccines
require an adjuvant to induce immunogenicity though it is important to note that the
partial uptake of only the peptide and not the adjuvant by the antigen presenting cells can
be responsible for inducing tolerance instead of immunity [89]. Additionally, dendritic
cells ex-vivo loaded with neoantigens as mentioned above are being explored in healthy LS
and LS-CRC patients without serious adverse effects in most patients [56]. The response
of peptide based vaccines can also be improved by taking longer peptides that code for
multiple epitopes. RNA vaccines additionally activate TLR3, TLR7 and TLR8 responses
mimicking adjuvant-induced inflammatory effects and are easier to produce than peptide
vaccines but they are subject to easy degradation by RNAses and have reduced uptake
by antigen presenting cells [90]. Encapsulation of synthetic DNA and RNA in nanoparti-
cle formulation has been shown to prevent degradation, improve its bioavailability and
facilitate the targeted and controlled delivery to antigen presenting cells [91,92].
Vaccine formulation consists of a challenging preclinical stage of development in
which neoantigens are tested for their pharmacokinetic properties such as absorption,
distribution, metabolism, excretion and clearance [93]. While small molecules can enter
cells easily through diffusion, synthetic peptides undergo a complex set of processes that
include peptide cleavage and presentation before finally being able to bind to their specific
receptors on the cell [94]. This further complicates the process of conducting in-vitro or
in-vivo pharmacological and immunological assays to track the pharmacokinetic properties
of neoantigens. Perhaps this is the reason why, the testing for peptide toxicity in animal
models is more often skipped and safety assessments are directly performed in phase
I clinical trials in humans. Use of animal models for neoantigen targeting therapies is
also particularly unfeasible because self-peptides and neoantigens may be significantly
different between species. During the selection of neoantigens, it is prioritised to select for
neoantigens that are shared among more patients. However, batch manufacturing for even
a small set of patients requires GMP facilities. This process is still not very cost effective.
5.4. Immune Evasion and Immunosuppression
The potency of neoantigen targeting therapies in LS and CMMRD is hampered by
the immune evasion mechanisms exerted by the tumour. If cells can evade eradication,
equilibrium follows for a certain period of time [67]. Immune escape then eventually
occurs which allows the remaining cells to evade detection by the immune system and
undergo unrestrictive proliferation. Moreover, the downregulation of transcripts of highly
immunogenic neoantigens to evade recognition is also seen [85]. Another overriding
immune escape mechanism is the evidence for mutations in a microsatellite region of
β2-microglobulin (B2M) gene which forms an essential component of the (neo)antigen
presentation machinery of the MHC class I protein with the mutation leading to total loss of
HLA expression observed in nearly 30% of MSI-H CRC patients [95–97]. Apart from B2M
itself, mutations in the gene NLRC5, which is a direct transactivator of B2M, TAP1 and HLA
A/B/C/D/E/F/G, have been reported in MSI-H CRCs. This leads to the a disabled antigen
presentation machinery, enabling immune escape, hence favouring expansion of tumour
cells [98]. Additionally, frameshift mutations in RFX5 observed in 40% of MSI-H CRCs
and promoter methylation of CTIIA genes restrict IFNγ-inducible HLA class II antigen
presentation [99,100]. While the B2M mutations predominate LS-CRC, inactivation of TAP1
or TAP2 proteins are more common in sporadic MSI-H CRC. This is important because
it has an effect on the expression levels of additional HLA classes and also on NK cell
activity [101].
Another interesting correlation between B2M mutation and immunosuppression is
seen in the infiltration of Foxp3+ regulatory T cells (Tregs). In a study of LS-CRC patients
it was shown that B2M wild type tumours had a higher frequency of Tregs and hence
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increased immunosuppression as compared to the B2M mutant tumours [102]. It was
hypothesized that this may provide a survival benefit for the B2M mutant tumours in an
environment where in spite of low infiltration of Tregs, the active immune system fails to
induce a response by not recognising the tumour cells [102]. Moreover, in another study
concerning an LS-CRC patient, a high density of immunosuppressive myeloid-derived
suppressor cells (MDSCs) was seen. The authors hypothesised that MDSCs were the reason
for the reduced activation of CD8+ T cells in the patient [85]. In this study, the authors
also linked the increased infiltration of Tregs with a negative prognosis. This warrants
further study into targeting MDSCs and Tregs in LS-CRC patients to overcome immuno-
suppression. Furthermore, it has been reported in a patient with MMR-deficient colon
adenocarcinoma that NK cell activity has been affected by the increased frequency of M2
macrophages which interfere with NK degranulation, thereby hampering the response and
shedding light on the immunosuppressive tumour microenvironment in MMR-deficient
patients [41]. It is also to be noted that DC maturation is impaired in MSI-H CRCs that
have high Treg infiltration which impedes neoantigen presentation in these patients [75],
although vaccination with mature DCs, that are loaded with immunogenic neoantigens
could potentially be a successful regimen.
A dominant channel to escape immune surveillance is the presence of immune check-
point blockade molecules that can cause exhaustion of CD8+ T cells. These then fail to
proliferate in response to antigen and they lack critical anticancer effector functions such
as cytotoxicity and IFNγ secretion [39]. Interestingly, it has also been shown that B2M
mutant MSI-H CRCs have a higher frequency of PD-1 positive T cells as compared to B2M
wild type MSI-H CRCs, thereby further hampering the immune response [103]. While
the promise of checkpoint inhibitor therapy in this regard has been discussed before, it is
important to address the cases where the MMR-deficient CRC patients showed resistance
or showed disease progression despite pembrolizumab treatment [104]. The sequencing of
metastases from patients who developed progressive disease revealed mutations in B2M,
though such mutations were not observed in the primary tumour. The lack of suitable
biomarkers for predictability of the efficacy of immune checkpoint therapy is a major
setback since 12% to 40% of all MMR deficient metastatic CRC patients show resistance,
including acquired resistance in patients that were sensitive to the therapy initially [105].
Resistance to anti-PD-1 therapy in MSI-H CRC patients was attributed to homozygous loss
of function mutations in IFNγ receptor Janus Kinase 1 (JAK1) [106]. It is hypothesised that
the loss of JAK1 makes the tumour cells resistant to IFNγ secretion from cytotoxic T cells,
thereby the dampening the anti-proliferative effect of IFNγ, as depicted in Figure 4.
An LS patient with metachronous urothelial and colon cancer being treated with
anti-PD-1 therapy presented differential response to the therapy. Where no response was
observed in the colonic lesion, pseudoprogression (increased tumour size during imaging
due to infiltration of lymphocytes and macrophages which has positive connotations for
immunotherapy) was seen for the ureteral lesion [107]. In the study concerning LS-CRC
patients where two distinct patient groups were identified, the group of patients with high
TMB and resembling sporadic MSI-H cancer type had lower expression of checkpoint genes
such as PD-1, PD-L1 and CTLA-4 in the tumour as compared to the reference mucosa. It is
hypothesised that the tumours in this subgroup have already undergone immune escape
and have markedly lower infiltration of T cells thereby questioning the efficacy of immune
checkpoint inhibition therapy in this subgroup [36,68]. Activation of the Wnt/β-catenin
pathway in metastatic melanoma has been shown to reduce T cell infiltration and hence
reduce IFNγ secretion as well as conferring resistance to immune checkpoint therapy,
though similar studies in LS and CMMRD are lacking [108]. There is a scarcity of studies
done to assess exclusive escape mechanisms or its implications in CMMRD patients and
given the complexity of these suppressive processes, the need cannot be more emphasised.
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A study demonstrated the effect of inhibition of cell cycle proteins cyclin dependent
kinase 4 and 6 (CDK4 and CDK6) in upregulation of B2M and other proteins of MHC
class I machinery. I additi n it was found to increase infiltration of tumour-infiltrating
T cells and decrease Tregs, the effects of which were enha ced by immune checkpoint
therapy [109]. This is an encouraging proposal to look out for and test to enhance the
efficacy of neoantigen targeting therapies in LS and CMMRD.
6. Conclusions
LS and CMMRD-related cancers provide a unique challenge to current treatment
strategies with more potential for neoantigen-targeting therapies on account of high TMB.
This is appealing for preventive purposes, since LS and CMMRD patients have a very
high risk of developing cancer and LS associated tumours express shared neoantigens.
These shared neoantigens have been shown to give rise to specific CTLs which are also
present in healthy LS carriers [52]. However, it must be considered that preventive neoanti-
gen vaccination could lead to selection of tumours that do not express these neoantigens
anymore. In addition, there are major considerations for CMMRD patients for whom the
predicted neoantigens could be present in all cells because all cells are MMR deficient. This
calls for the identification of tumour-specific neoantigens which are not present in other
MMR-deficient cells, to avoid the risk of significant toxicity. The overwhelming tumour
heterogeneity in LS and CMMRD patients originating from MMR defect and giving rise to
complex tumourigenesis pathways and diverse neoantigen repertoires, does not only make
the choice of vaccine neoantigen more complicated but it also makes it tougher to predict
response of the different tumours within the patient and across patient populations. The
use of more accurate neoantigen immunogenicity prediction algorithms and neoantigen
profiling across patients is required, since larger studies regarding neoantigen formation
and immune responses in CMMRD patients is particularly lacking. It is then most suit-
able to combine a neoantigen targeting therapy to induce a potent T cell response with
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immune checkpoint therapy to overcome the immunosuppressive environment. Potential
biomarkers in LS and CMMRD patients that can predict the response to neoantigen and
immune checkpoint therapy are necessary since immune-evasion mechanisms in these
cancers are complicated.
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